Congress passed legislation providing a pathway for biosimilars over a decade ago, and the widespread adoption of biosimilars has been slower than many policymakers would have liked. As a result, biosimilars enjoy many distinct and preferential treatments under the various government programs.

Points of discussion will include:

• Understanding how biosimilars are treated and impacted under each of the government pricing programs
  • Medicare
  • Medicaid
  • PHS 340B
• Identifying the impact biosimilars play in the Medicare Drug Price Negotiation process
• Evaluating why have stakeholders are hesitant to use available biosimilars
• Assessing the various measures currently in place at the federal and state level to encourage the movement to biosimilars
  • Forecasting the future of biosimilars and its impact on the government pricing programs